For the Inventor, By the Inventor

Enter assignee name

Boston, MA, United States of America

Dana-Farber-Cancer Institute Inc.

USPTO Granted Patents = 1,210

CIPO Patents = 57

EPO Patents = 303

Trademarks = 36

Forward Citations = 10,807

Loading Chart...

Loading Chart...

1,377 inventors (with patents filed for the assignee):

Nathanael Schiander Gray (140 out of 173 patents)

Gordon James Freeman (80 out of 90 patents)

James Elliott Bradner (60 out of 61 patents)

4. Loren D Walensky (52 out of 53 patents)

5. Wayne A Marasco (52 out of 55 patents)

6. Donald W Kufe (49 out of 59 patents)

7. Tinghu Zhang (47 out of 49 patents)

8. Bruce M Spiegelman (38 out of 42 patents)

9. Jun Qi (37 out of 37 patents)

10. Hwan Geun Choi (32 out of 51 patents)

11. Pasi Antero Janne (32 out of 32 patents)

12. Joseph G Sodroski (32 out of 33 patents)

13. Matthew Meyerson (31 out of 31 patents)

14. Kenneth Carl Anderson (30 out of 38 patents)

15. Glenn Dranoff (28 out of 30 patents)

Core Competencies:

Cancer Vaccines

Protein Degradation

Chromatin Remodeling

T Cell Receptors

Kinase Inhibitors

EGFR Inhibitors

Biomarkers

Nucleic Acid Constructs

Antibody Therapeutics

CRISPR Systems

Anemia Treatment

MicroRNA Signatures

1,210 patents: Sort by Forward Citations

1. 12509455 - Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof (2025-12-30),

2. 12497398 - Potent and selective covalent inhibitors of serine-arginine protein kinase (SRPK) 1 and SRPK2 and uses thereof (2025-12-16),

3. 12496348 - Small molecule target bromo/acetyl proteins and uses thereof (2025-12-16),

4. 12491251 - Degraders of cyclin-dependent kinase 7 (CDK7) and uses thereof (2025-12-09),

5. 12479852 - Compounds, compositions, and methods for protein degradation (2025-11-25),

6. 12479847 - Pyrrolopyrimidine inhibitors of wild-type and mutant forms of LRRK2 (2025-11-25),

7. 12478665 - Cancer vaccine compositions and methods for using same to prevent and/or treat cancer (2025-11-25),

8. 12473334 - SWI/SNF family chromatin remodeling complexes and uses thereof (2025-11-18),

9. 12466809 - CDK2/5 degraders and uses thereof (2025-11-11),

10. 12454572 - Methods of treating anemia in myelodysplastic syndromes (2025-10-28),

11. 12448462 - Antibodies against MUC1 (2025-10-21),

12. 12448429 - T cell receptors specific to b-cell maturation antigen for treatment of cancer (2025-10-21),

13. 12441775 - BCL-W polypeptides and mimetics for treating or preventing chemotherapy-induced peripheral neuropathy and hearing loss (2025-10-14),

14. 12441685 - Compounds and methods for treating cancer (2025-10-14),

15. 12440451 - Compositions and methods using an epigenetic inhibitor (2025-10-14),

Dana-Farber Cancer Institute is a world-renowned non-profit organization dedicated to providing expert, compassionate care to cancer patients while conducting groundbreaking research to find cures and preventions for all types of cancer. With a team of highly skilled oncologists, scientists, and healthcare professionals, Dana-Farber works tirelessly to improve the lives of those affected by cancer and strives for excellence in patient care, education, and clinical research.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

1,210 Patents

#5 in Boston, MA

#21 in Massachusetts

#409 in US

#813 in the World

Boston, MA, United States of America

Dana-Farber-Cancer Institute Inc.

Forward Citations = 10,807

1,377 inventors:

Nathanael Schiander Gray (140 out of 173 patents)

Gordon James Freeman (80 out of 90 patents)

James Elliott Bradner (60 out of 61 patents)

4. Loren D Walensky (52 out of 53 patents)

5. Wayne A Marasco (52 out of 55 patents)

Please report any incorrect information to support@idiyas.com

Loading…